跳至主要内容
临床试验/NCT00997269
NCT00997269已完成不适用

Benefit of CoQ-10 in Patients on Statins

Stony Brook University2 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
37
试验地点
2
主要终点
Pain scores should be reduced

研究概览

简要总结

This study will investigate whether a supplement called co-enzyme Q10 can help ease or eliminate some of the side effects that result from taking statin medications. These side effects include muscle pain, fatigue or muscle cramping.

详细描述

Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and muscle function.

This objective will be achieved in a randomized, placebo-controlled double blind trial by assessing the degree of muscle symptoms and interference of pain with daily activities, aerobic capacity, and muscle function before and after supplementation with either coQ10 or placebo in groups of statin-treated subjects.

Specific Aim 2: to examine changes at a molecular/cellular level that are associated with improved pain and muscle function in statin-treated subjects supplemented with coQ10.

This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients before and after supplementation with coQ10 or placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult men and women 21 years and older taking statin medications for hyperlipidemia under the current National Cholesterol Education Program guidelines (NCEP III) and complaining of myopathic symptoms.

排除标准

  • diagnosis of cancer;
  • acute illness of any sort;
  • hemoglobin less than 12,
  • creatinine greater than 1.5 mg/dl;
  • liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper limit of normal;
  • use of certain medications or nutritional supplements within the past month;
  • untreated hypertension (diastolic BP> 100 mm HG);
  • diagnosis of diabetes mellitus (fasting blood glucose > 126 mg/dl);
  • untreated hypothyroidism;
  • overt congestive heart failure (by physical exam);
  • active inflammatory diseases such as rheumatoid arthritis, lupus, etc.,
  • bleeding disorders;
  • history of adverse reactions besides myopathy associated with the use of statins;
  • any previous adverse reaction to coQ10 or to multivitamin supplements containing coQ10;
  • plasma CPK levels > 3 times the upper normal limit; OR
  • congenital myopathies and/or neuromuscular degenerative diseases.

结局指标

主要结局

Pain scores should be reduced

时间窗: 8 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验